Therapeutics
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
|---|---|---|---|---|
| PAR-20-253 | Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 07/07/2020 | 05/30/2023 |
| RFA-RM-20-020 | NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional) | NIH | 05/21/2020 | 09/30/2020 |
| PAR-20-180 | Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) | NIH | 04/30/2020 | 09/07/2023 |
| PAR-20-161 | Catalyzing Innovation in Pediatric Pharmacology Clinical Trial Design and Resource Access (X01 Clinical Trial Not Allowed) | NIH | 04/02/2020 | 03/17/2023 |
| PAR-20-157 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) | NIH | 03/31/2020 | 05/07/2023 |
| PAR-20-159 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | NIH | 03/31/2020 | 05/07/2023 |
| PA-20-146 | NIDA Small Research Grant Program (R03 Clinical Trial Required) | NIH | 03/24/2020 | 05/07/2023 |
| RFA-AI-20-024 | Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed) | NIH | 03/23/2020 | 07/28/2020 |
| RFA-AI-20-010 | Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed) | NIH | 03/06/2020 | 07/28/2020 |
| PAR-20-116 | Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | NIH | 02/24/2020 | 11/18/2021 |
| RFA-AG-21-003 | New/Unconventional Animal Models of Alzheimers Disease (R24 Clinical Trial Not Allowed) | NIH | 01/13/2020 | 10/07/2020 |
| RFA-OD-20-004 | INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed) | NIH | 12/13/2019 | 11/03/2021 |
| PAR-20-072 | NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) | NIH | 12/09/2019 | 09/07/2022 |
| PAR-20-063 | NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) | NIH | 11/22/2019 | 01/07/2023 |
| PAR-20-030 | HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) | NIH | 10/18/2019 | 12/03/2020 |
| PAR-19-385 | Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R21 Clinical Trial Not Allowed) | NIH | 09/30/2019 | 11/16/2021 |
| PAR-19-386 | Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R01 Clinical Trial Not Allowed) | NIH | 09/30/2019 | 11/16/2021 |
| RFA-HL-20-023 | Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) | HHS | 09/09/2019 | 08/11/2021 |
| RFA-HL-20-022 | Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) | HHS | 09/09/2019 | 08/11/2021 |
| RFA-HL-20-027 | Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) | HHS | 09/09/2019 | 08/11/2021 |
| PAR-19-357 | Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed) | HHS | 09/03/2019 | 01/10/2022 |
| PAR-19-364 | Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed) | HHS | 09/03/2019 | 01/10/2022 |
| PAR-19-356 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS | 08/28/2019 | 07/20/2022 |
| PAR-19-328 | Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | HHS | 08/05/2019 | 09/08/2022 |
| PAR-19-325 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | NIH | 07/30/2019 | 02/11/2022 |
| PAR-19-305 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) | NIH | 06/25/2019 | 07/16/2022 |
| PAR-19-304 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) | NIH | 06/25/2019 | 07/16/2022 |
| PAR-19-294 | Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) | NIH | 06/06/2019 | 11/12/2021 |
| PAR-19-289 | Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) | NIH | 05/29/2019 | 09/07/2022 |
| PAR-19-278 | Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | NIH | 05/08/2019 | 12/17/2021 |
| PA-19-237 | Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) | NIH | 04/03/2019 | 05/07/2022 |
| PAR-19-194 | Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) | NIH | 02/22/2019 | 05/07/2022 |
| PAR-19-193 | Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) | NIH | 02/22/2019 | 05/07/2022 |
| PAR-19-189 | Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | NIH | 02/21/2019 | 01/07/2022 |
| PAR-19-078 | Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-082 | Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-083 | Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-067 | Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed) | NIH | 11/13/2018 | 01/07/2022 |
| PA-19-066 | Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) | NIH | 11/13/2018 | 01/07/2022 |
| PAR-18-950 |
Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional) | NIH | 10/5/2018 | 12/11/2020 |
| PA-19-020 |
Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) | NIH | 10/5/2018 | 1/7/2022 |
| PAR-18-952 |
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | NIH | 10/4/2018 | 10/25/2021 |
| PAR-18-953 |
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | NIH | 10/4/2018 | 10/25/2021 |
| PA-18-937 | Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional) | NIH | 9/26/2018 | 1/7/2022 |
|
Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) |
NIH |
9/26/2018 |
1/7/2022 |
|
|
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional) |
NIH |
9/10/2018 |
9/7/2021 |
|
|
Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02 Clinical Trials Not Allowed) |
NIH |
8/31/2018 |
4/29/2021 |
|
| RFA-MH-19-240 | Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) | NIH | 8/9/2018 | 11/20/2020 |
| PAR-18-895 | CNS-Targeted Drug Delivery Strategies for HIV (R01 Clinical Trial Not Allowed) | NIH | 8/8/2018 | 1/7/2021 |
|
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required) |
NIH |
2/27/2018 |
1/7/2021 |
|
|
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required) |
NIH |
2/27/2018 |
1/7/2021 |
|
|
Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed) |
NIH |
2/1/2018 |
5/7/2021 |
|
|
Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional) |
NIH |
3/1/2018 |
5/7/2021 |
|
|
Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional) |
NIH |
3/1/2018 |
5/7/2021 |
|
|
Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional) |
NIH |
3/1/2018 |
5/7/2021 |
|
|
Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional) |
NIH |
1/2/2018 |
1/7/2021 |
|
|
Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01) and Clinical Trial Optional |
NIH |
1/2/2018 |
1/7/2021 |
|
|
Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional) |
NIH |
12/19/2017 |
1/7/2021 |
|
|
Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed) |
NIH |
12/18/2017 |
1/7/2021 |
|
|
Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required) |
NIH |
12/6/2017 |
1/7/2021 |
|
|
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-Term Outcomes (R34-Clinical Trials Required) |
NIH |
12/6/2017 |
1/7/2021 |
|
|
Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21- Clinical Trial Required) |
NIH |
11/21/2017 |
1/7/2021 |
|
|
Biology of Lung, and Head and Neck Preneoplasias (R01) |
NIH |
8/15/2017 |
1/7/2021 |
|
|
Biology of Lung, and Head and Neck Preneoplasias (R21) |
NIH |
8/16/2017 |
1/7/2021 |
|
|
Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21) |
NIH |
8/31/2017 |
9/7/2020 |
|
|
Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01) |
NIH |
8/31/2017 |
9/7/2020 |
|
|
Assay development and screening for discovery of chemical probes or therapeutic agents (R01) |
NIH |
7/27/2017 |
9/7/2020 |
|
|
Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) |
NIH |
5/12/2017 |
9/7/2020 |
|
|
Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01) |
NIH |
5/12/2017 |
9/7/2020 |
|
|
Mechanisms of Alcohol-associated Cancers (R01) |
NIH |
3/13/2017 |
9/7/2020 |
|
|
Mechanisms of Alcohol-associated Cancers (R21) |
NIH |
3/13/2017 |
9/7/2020 |
|
|
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required) |
NIH |
02/27/2018 |
01/07/2021 |